Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Other

• Participation in another clinical trial using telemonitoring.
• Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
• Patient deprived of their liberty or under protective custody or guardianship.

• Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
• Patients ≥18 years of age.
• Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
• Life expectancy > 6 months as per investigator estimate.
• Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
• Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
• Affiliated to the social security system or equivalent health insurance.
• Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
• Patient has access to a computer, tablet, or smartphone connected to the Internet.